Trans-resveratrol
Trans-Resveratrol · also known as Trans-resveratrol, Japanese knotweed extract
In laboratory experiments, resveratrol can affect pathways including SIRT1, AMPK-PGC-1α and NF-κB. Randomized human trials give some evidence of lower NF-κB activity, but direct activation of SIRT1 is disputed, and human results for mitochondrial biogenesis and Nrf2-related effects are inconsistent.
Clinical uses and human evidence
Osteoarthritis pain
High blood pressure
Studies (2)
- Gu 2022 · Int J Clin Pract · Meta-analysis · n=1151 — Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
- Shen 2026 · In Vivo · Meta-analysis · n=2551 — Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases
Blood sugar and insulin resistance
Studies (2)
- Zeraattalab-Motlagh 2021 · Am J Clin Nutr · Systematic review — The effects of resveratrol supplementation in patients with type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials
- Shen 2026 · In Vivo · Meta-analysis · n=2551 — Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases
High LDL cholesterol
Studies (2)
- Li 2024 · Prostaglandins Other Lipid Mediat · Meta-analysis — Efficacy of resveratrol supplementation on lipid profile parameters: An umbrella of meta-analysis
- Shen 2026 · In Vivo · Meta-analysis · n=2551 — Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases
High triglycerides
Body weight and body fat
Studies (2)
- Abu-Zaid 2025 · Eat Weight Disord · Meta-analysis — The effect of resveratrol supplementation on obesity indices: a critical umbrella review of interventional meta-analyses
- Shen 2026 · In Vivo · Meta-analysis · n=2551 — Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases
Fatty liver and liver enzymes
Studies (2)
Inflammation markers (such as CRP)
Mechanisms of action
Inhibition of NF-κB / AP-1, the master switches of pro-inflammatory transcription
Randomized human trials at usual doses observed lower NF-κB activity, but results differ across populations and markers. The upstream mechanism of this effect has not been established, and the finding does not show that SIRT1 directly deacetylates NF-κB p65.
References (3)
- Faghihzadeh et al. 2014 · Human randomized placebo-controlled trial: in patients with fatty liver, 500 mg/day for 12 weeks lowered NF-κB activity compared with placebo
- Samsami-Kor et al. 2015 · Human randomized placebo-controlled trial: in patients with ulcerative colitis, 500 mg/day for 6 weeks lowered NF-κB activity in peripheral blood mononuclear cells
- Saldanha et al. 2016 · Human randomized crossover trial: in patients with chronic kidney disease, 500 mg/day for 4 weeks did not significantly change NF-κB gene expression
AMPK sensing of cellular energy deficit and metabolic reprogramming
A human randomized crossover trial observed muscle AMPK activation after 150 mg/day, but another randomized trial did not reproduce it. This may be a weak, indirect effect that depends on context.
Sirtuin-dependent protein deacetylase activation
Direct allosteric activation of SIRT1 varies with the substrate used in testing, and the conclusions remain disputed. SIRT1 protein can increase in humans, but more protein does not mean higher enzyme activity. Evidence for indirect effects, such as those through phosphodiesterase inhibition, is also insufficient at usual doses in humans.
References (5)
- Pacholec et al. 2010 · In-vitro enzyme study: results differed from those of Hubbard et al.; direct activation depended on the test substrate and its hydrophobic residues
- Hubbard et al. 2013 · In-vitro enzyme study: results differed from those of Pacholec et al.; direct activation depended on the test substrate and its hydrophobic residues
- Price et al. 2012 · Mouse study: some metabolic and mitochondrial responses depended on SIRT1, but this does not show direct binding and activation of SIRT1 in humans
- Bo et al. 2018 · Human randomized trial: SIRT1 protein increased in the 500 mg/day group; the link between H3K56 acetylation changes and SIRT1 comes from a post hoc stratified analysis
- Williams et al. 2014 · Human randomized crossover trial: after a single 300 mg dose, muscle nuclear SIRT1 activity and p53 acetylation did not change significantly
PGC-1α-driven mitochondrial biogenesis and proliferation
In some human studies, PGC-1α protein rose, but mitochondrial content did not increase with it, and changes in respiratory function do not on their own prove mitochondrial biogenesis. In humans, SIRT1-mediated mitochondrial biogenesis and its upstream mechanisms remain uncertain.
References (3)
- Timmers et al. 2011 · Human randomized crossover trial: after 150 mg/day for 30 days, muscle PGC-1α protein and citrate synthase activity rose, but mitochondrial content did not change
- Alway et al. 2017 · Human randomized trial of resveratrol plus exercise: at 500 mg/day with exercise, the group-by-time interaction for mitochondrial volume density was not significant
- Price et al. 2012 · Mouse study: mitochondrial biogenesis and functional changes were observed, and these were SIRT1-dependent
Nrf2/ARE activation of endogenous antioxidant enzymes
Some studies suggest resveratrol has Nrf2-related effects, and NQO1 changed in a small human tissue study, but the pathway and dose dependence are still unclear. Human evidence for resveratrol alone is inconsistent. Changes in SOD or Nrf2 gene expression are not enough on their own to prove ARE activation.
References (4)
- Cai et al. 2015 · Small human tissue study: in the 5 mg/day group, NQO1 in colorectal mucosa was higher than in untreated controls; the 1 g/day group did not show the same result
- Ghanim et al. 2011 · Human controlled crossover trial: a combination of resveratrol and grape polyphenols increased Nrf2 binding to target sequences and NQO1 expression, but this cannot be attributed to resveratrol alone
- Seyyedebrahimi et al. 2018 · Human randomized trial: Nrf2 and SOD gene expression rose in peripheral blood mononuclear cells in the 800 mg/day group
- Saldanha et al. 2016 · Human randomized crossover trial: 500 mg/day for 4 weeks did not significantly change Nrf2 expression or antioxidant markers in patients with chronic kidney disease
Safety and drug interactions
Additive bleeding risk
Has antiplatelet activity. Each of these has a mild antiplatelet or fibrinolytic effect. Alone, the effect is usually small, but when several are combined, the tendency to bleed becomes more noticeable. Stop them 1–2 weeks before surgery or a tooth extraction, and watch for gum bleeding or more bruising.
Inhibition of drug metabolism (CYP3A4 and others)
Inhibits CYP3A4 and CYP2C9. Each of these can inhibit the liver enzymes that metabolize drugs (mainly CYP3A4) or drug transporter proteins, raising blood levels of some prescription drugs.
With Tamoxifen / aromatase inhibitors Note
Weak estrogen-like activity. People with hormone-sensitive tumors should use caution.